52nd week of 2014 patent applcation highlights part 41 |
Patent application number | Title | Published |
20140377247 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA - Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders. | 2014-12-25 |
20140377248 | METHOD FOR THE MANUFACTURING OF DI-CHAIN PROTEINS FOR USE IN HUMANS - This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor Xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use. The invention further relates to novel di-chain clostridial neurotoxins and nucleic acid sequences encoding such novel di-chain clostridial neurotoxins. | 2014-12-25 |
20140377249 | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND COLLAGENASE FOR THE TOPICAL TREATMENT OF WOUNDS, BURNS AND ULCERS - The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars. | 2014-12-25 |
20140377250 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE, ENHANCING IMMUNOTHERAPY, AND INCREASING VACCINE POTENCY - Compositions including at least one PNP inhibitor or at least one PNP inhibitor in combination with one or more agents identified as endogenous adjuvants useful for enhancing the potency of vaccine and cancer immunotherapies being administered for the prevention or treatment of infectious diseases or cancer. The compositions may be formulated as pharmaceutical dosage forms and components may be assembled as kits. Methods for increasing the levels of endogenous adjuvants to enhance the immunogenicity of an antigen as well as to augment the potency of vaccine and cancer immunotherapies are also disclosed. | 2014-12-25 |
20140377251 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY - Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 anti body in vivo. | 2014-12-25 |
20140377252 | METHOD FOR PREDICTING THE RESPONSE TO TREATMENT WITH AN HER2-BLOCKING AGENT - The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer. | 2014-12-25 |
20140377253 | FC VARIANTS - The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors. | 2014-12-25 |
20140377254 | SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR - An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH | 2014-12-25 |
20140377255 | 4-1BB BINDING MOLECULES - The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 2014-12-25 |
20140377256 | OPTIMIZED FC VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2014-12-25 |
20140377257 | COMBINATION THERAPY FOR B CELL DISORDERS - The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist. | 2014-12-25 |
20140377258 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators - Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders. | 2014-12-25 |
20140377259 | METHODS FOR INHIBITING HIV-1 REPLICATION INVOLVING THE ADMINISTRATION OF AN ANTI-CCR5 RECEPTOR MONOCLONAL ANTIBODY AND SMALL MOLECULE CCR5 RECEPTOR ANTAGONIST - This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5 | 2014-12-25 |
20140377260 | PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS SA2074 PROTEIN - The present invention relates to methods of inducing an immune response to | 2014-12-25 |
20140377261 | VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME - Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. | 2014-12-25 |
20140377262 | HUMAN MONOCLONAL ANTIBODIES BROADLY PROTECTIVE AGAINST INFLUENZA B VIRUS AND METHODS OF USING THE SAME - Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject. | 2014-12-25 |
20140377263 | LET-7 MICRORNA AND MIMETICS THEREOF AS THERAPEUTICS FOR CANCER - The present invention relates to methods to treat or prevent cancers in a subject, in particular the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have reduced expression or are lacking in the cancer stem cells. In some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs. In alternative embodiments, the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have increased expression levels in the cancer stem cells. Another aspect of the present invention relates to methods to enrich for a cancer stem cell population. Another aspect of the present invention relates to methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells. | 2014-12-25 |
20140377264 | Polypeptide Formulation - The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same. | 2014-12-25 |
20140377265 | ANTICOAGULANT ANTIDOTES - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. | 2014-12-25 |
20140377266 | Methods and Compositions Involving NKG2D Inhibitors and Cancer - Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer. | 2014-12-25 |
20140377267 | ANTIBODIES TO CROSS-LINKED AMYLOID BETA OLIGOMERS - The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease. | 2014-12-25 |
20140377268 | CLEAVAGE INHIBITORS OF TRANSFORMING GROWTH FACTOR BETA TYPE I RECEPTOR AND USES THEREOF IN CANCER THERAPY - Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (TβRI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of TβRI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of TβRI, which is a product of TβRI cleavage. | 2014-12-25 |
20140377269 | MULTIVALENT ANTIBODY ANALOGS, AND METHODS OF THEIR PREPARATION AND USE - Multivalent antibody analogs that co-engage at least two different antigens or epitopes (also referred to “targets”, used interchangeably throughout), are provided, as well as methods for their production and use. | 2014-12-25 |
20140377270 | OPTIMIZED ANTIBODY VARIABLE REGIONS - The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 2014-12-25 |
20140377271 | NATURALLY OCCURRING AUTOANTIBODIES AGAINST ALPHA-SYNUCLEIN THAT INHIBIT THE AGGREGATION AND CYTOTOXICITY OF ALPHA-SYNUCLEIN - The present invention refers to human antibodies which are directed against α-Synuclein (α-Syn) and their use in medicine and diagnosis. | 2014-12-25 |
20140377272 | ANTI-HER3 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2014-12-25 |
20140377273 | ANTI-HER3 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2014-12-25 |
20140377274 | USE OF 2-DEOXY-D-GLUCOSE TO SENSITIZE CANCER CELLS TO AN AGENT THAT ACTIVATES THE EXTRINSIC APOPTOTIC PATHWAY - Methods for sensitizing a solid tumor cell to an agent that activates the extrinsic apoptotic pathway and treating a solid tumor using a combination of 2-deoxy-D-glucose and an agent that activates the extrinsic apoptotic pathway are described. | 2014-12-25 |
20140377275 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY FORMULATIONS - The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof. | 2014-12-25 |
20140377276 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 2014-12-25 |
20140377277 | TREATMENT OF VASCULOPROLIFERATIVE CONDITIONS WITH LRG1 ANATGONISTS - This invention relates to the field of molecular physiology. Specifically, this invention relates to the treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions. | 2014-12-25 |
20140377278 | Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders - The present invention relates to the discovery that the disruption of inflammasome function leads to an altered microbiota that affects the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and determining the relative proportions of the constituents of a subject's microbiota, methods of modifying an altered microbiota population in a subject, and compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. | 2014-12-25 |
20140377279 | RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them. | 2014-12-25 |
20140377280 | NON-SIALYLATED ANTI-INFLAMMATORY POLYPEPTIDES - This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders. | 2014-12-25 |
20140377281 | LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE - The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same. | 2014-12-25 |
20140377282 | ANTI-KDR ANTIBODIES AND METHODS OF USE - The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity. | 2014-12-25 |
20140377283 | PREPARATION USEFUL FOR, AND METHOD FOR TREATMENT OF NEONATAL ALLOIMMUNE THROMBOCYTOPENIA (NAIT) - A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy. | 2014-12-25 |
20140377284 | HUMANIZED ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF - The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment. | 2014-12-25 |
20140377285 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS - The present invention provides for methods and pharmaceutical compositions for treating disorders using treatment regimens involving multiple agents. In one aspect, a method of treatment is provided resulting in reduced toxicity and/or synergistic effect by administration according to a described dosing schedule. | 2014-12-25 |
20140377286 | DETECTION AND TREATMENT OF CD30+ CANCERS - The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30 | 2014-12-25 |
20140377287 | ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF - Described herein are compositions and methods of use of antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody or antigen-binding fragment thereof, conjugated to one or more cytotoxic drugs. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. More preferably, the antibody is humanized. Preferably the drug is SN-38, pro-2-pyrrolinodoxorubicin, paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD or MMAF. The compositions and methods are of use to treat Trop-2 expressing cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer. Preferably, the cancer is one that is resistant to one or more standard cancer therapies. More preferably, the anti-Trop-2 antibody binds to Trop-2 expressed on normal cells, but administration of the anti-Trop-2 ADC to human cancer patients at a therapeutically effective dosage produces only limited toxicity. | 2014-12-25 |
20140377288 | COMPOSITIONS AND METHODS RELATED TO DNA DAMAGE REPAIR - The present invention provides compositions and methods for treating a cancer associated with elevated expression and/or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5. In some embodiments, the present invention provides compositions and methods for identifying elevated expression or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5. | 2014-12-25 |
20140377289 | Metallodrugs Having Improved Pharmacological Properties, and Methods of Manufacture and Use Thereof - It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target. | 2014-12-25 |
20140377290 | SITE-SPECIFIC GLP-2 CONJUGATE USING AN IMMUNOGLOBULIN FRAGMENT - The present invention relates to a glucagon-like peptide-2 (GLP-2) conjugate comprising native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosia by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability. | 2014-12-25 |
20140377291 | GLYCOSPHINGOLIPIDS FOR USE IN MODULATING IMMUNE RESPONSES - Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein. | 2014-12-25 |
20140377292 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME - The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof. | 2014-12-25 |
20140377293 | METHODS FOR TREATING NEWLY DIAGNOSED MULTIPLE MYELOMA WITH 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH DEXAMETHASONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2014-12-25 |
20140377294 | ADENOVIRUSES EXPRESSING HETEROLOGOUS TUMOR-ASSOCIATED ANTIGENS - The present invention is directed to adenoviruses for use in cancer therapy which comprise one or more heterologous nucleic acid sequences encoding a tumor antigen, whereby the adenovirus expresses the tumor antigen(s) on its surface. | 2014-12-25 |
20140377295 | INFLUENZA VACCINES CONTAINING MODIFIED ADENOVIRUS VECTORS - This disclosure provides universal influenza vaccines which can provide extended protection for several years, provide improved protection to circulating influenza strains that were not predicted accurately for annual vaccine manufacturing, and provide protection against newly emerging strains of influenza virus which carry the potential for establishing global pandemics. | 2014-12-25 |
20140377296 | H3 INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 2014-12-25 |
20140377297 | RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM - The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions. | 2014-12-25 |
20140377298 | TREATMENT OF PIGS WITH PCV2 ANTIGEN - The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets. | 2014-12-25 |
20140377299 | IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore. | 2014-12-25 |
20140377300 | Tuberculosis Compositions And Methods Of Using The Same - The present disclosure provides fusion proteins comprising | 2014-12-25 |
20140377301 | Vault Compositions for Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity. | 2014-12-25 |
20140377302 | IMMUNOGENIC COMPOSITION - The invention provides immunogenic polysaccharide protein conjugates comprising capsular polysaccharides from | 2014-12-25 |
20140377303 | PHARMACEUTICAL PRODUCTS FROM FUNGAL STRAINS - Disclosed herein are compositions comprising an isolated cellulose degrading fungus and pharmaceutical substances produced by the fungus. | 2014-12-25 |
20140377304 | TREATMENT AND COMPOSITION FOR ACHIEVING SKIN ANTI-AGING BENEFITS BY CORNEUM PROTEASE ACTIVATION - Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing a combination of a cationic surfactant such as N,N,-dimethyldodecyl amine oxide (DMDAO), an anionic surfactant such as sodium dodecyl sulfate (SDS), or monoalkyl phosphate (MAP) and a chelating agent such as ethylene diamine tetraacetate (EDTA) to stimulate a chronic increase in the replacement rate of the skin's stratum corneum by means of corneum protease activation. This chronic, low level stimulation is effective to induce repair and replacement of the stratum corneum, epidermis, and dermis of the skin and improvements in the appearance, function, and anti-aging properties of the skin. | 2014-12-25 |
20140377305 | METHOD FOR TREATING DISEASE ASSOCIATED WITH TRANSCRIPTION ACTIVATION BY NF-KB - A method for treating a disease associated with transcription activation by NF-κB by administering a composition for inhibiting transcription activation by NF-κB to a patient in need of treatment of the disease. The composition contains a fraction having a molecular weight of 3,000 or less obtained by purifying a water extract of Sargassum horneri as an active ingredient. | 2014-12-25 |
20140377306 | RECOMBINANT VACCINE VIRUSES EXPRESSING IL-15 AND METHODS OF USING THE SAME - The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15. | 2014-12-25 |
20140377307 | USE OF INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE IN COMBINATION WITH OTHER THERAPEUTIC MODALITIES - The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent. | 2014-12-25 |
20140377308 | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES - The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity. | 2014-12-25 |
20140377309 | AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR (TLR) 13 - The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids. | 2014-12-25 |
20140377310 | METHODS TO TREAT ALLERGIC CONDITIONS - Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3. | 2014-12-25 |
20140377311 | METHOD OF PREVENTING ALLERGIES - The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies. | 2014-12-25 |
20140377312 | Transmucosal Administration System for a Pharmaceutical Drug - The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route. | 2014-12-25 |
20140377313 | Formulation for Providing an Enteric Coating Material - The present invention relates to an enteric coating formulation, as well as methods for preparing and using said enteric coating formulation. In particular, the invention relates to an enteric coating formulation that is made up of foodeous approved materials. | 2014-12-25 |
20140377314 | HIGHLY FUNCTIONAL COLORING MATERIAL AND PRODUCTION PROCESS FOR THE SAME - The present invention relates to a highly functional coloring material which causes less separation between a pigment and tabular inorganic powders and brings about less color separation and which is obtained by coating evenly a pigment on the surfaces of tabular colorless to white inorganic powders via a specific binder resin. The coloring material of the present invention does not bring about color deviation and color separation. | 2014-12-25 |
20140377315 | Oral Composition Indicative Of Proper Tooth Cleaning - The present invention provides an oral care composition for encouraging proper tooth cleaning, containing particulate materials which can be breakable under a brushing action with a brushing force from 0.1N to 5N. The particulate materials can have a particle size distribution characterized by (1) a change ratio of mean particle size before and after the brushing action is at least 20%, (2) a change ratio of D90 before and after the brushing action is at least 20%, (3) at least 5% of the particulate materials have a particle size greater than 200 μm before the brushing action, and (4) no more than 30% of the particulate materials have a particle size greater than 200 μm after the brushing action. The oral care composition can have a viscosity ranging from 10 to 90 BKU. | 2014-12-25 |
20140377316 | Home and personal care product and method for manufacturing the same - The present invention discloses a method for manufacturing home and personal care product and a method for manufacturing degreased coffee particles thereof. The home and personal care product comprises coffee particles with different sizes, in which the coffee particles are degreased by physical and chemical methods and then grinded to different sizes to meet the requirements of different products. Natural compositions from original coffee can be further added for enhancing the clean and care effects of the product. | 2014-12-25 |
20140377317 | 17-HYDROXYPROGESTERONE ESTER CONTAINING ORAL COMPOSITIONS AND RELATED METHODS - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 2014-12-25 |
20140377318 | ANTIMICROBIAL SANITIZER SYSTEMS AND METHODS OF KILLING OR INHIBITING PATHOGENS - Methods and systems for killing or inhibiting pathogens present in treatments area including but not limited to the nasal cavity, the vaginal area, and the anal area. The methods feature introducing a substrate with an antimicrobial metal into the treatment area. The substrate may be coated, lined, plated, or clad with the antimicrobial metal, either partially or entirely. Or, the substrate itself may be an antimicrobial metal. Antimicrobial metals include but are not limited to copper, zinc, silver, gold, and certain metal alloys. The step of directly contacting the substrate with antimicrobial metal to the treatment area kills or inhibits present pathogens. The antimicrobial metal may leave a trace amount of residue, which may continue to kill or inhibit pathogens after the system has been removed from the treatment area or penetrate into deeper layers of the treatment area. | 2014-12-25 |
20140377319 | ALTERING PROTEIN CONCENTRATIONS IN CEREBROSPINAL FLUID AND/OR BRAIN INTERSTITIAL FLUID - Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid. Additionally, methods are disclosed for treating neurodegenerative diseases and neurological disorders. | 2014-12-25 |
20140377320 | Selective Plasma Activation for Medical Implants and Wound Healing Devices - A treated surface of a device ( | 2014-12-25 |
20140377321 | BIOMEDICAL DEVICE, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF - A three-dimensional biomedical device having an osteoinductive first area with a controlled porosity and a second area, which is produced by laser technology from a powder including one of ceramics, metals, metal alloys, bioactive glasses, lead zirconate titanate and biocompatible polymers, or mixtures thereof. The ratio of the porosities from the second area to the first area is equal or less than one, preferably from 0.001 to 0.9. A method for manufacturing the device for fitting in a bone defect, wherein a virtual object is designed with a computer-aid designed software, and the device is manufactured by laser technology including layering a powder onto a plate ( | 2014-12-25 |
20140377322 | MULTI-LAYERED STRUCTURE FOR DRUG RESERVOIR AND DRUG ELUTING STENT INCLUDING THE SAME - Disclosed is a multi-layered structure for drug reservoir, comprising a first micelle layer for crosslinking and adhesion, comprising a drug, a multi-arm polymer, a phenol derivative, and a dopa derivative and having a one or two-layered structure; a second micelle layer for crosslinking, being stacked on the first micelle layer, comprising a drug, a multi-arm polymer, and a phenol derivative, and having a one or two-layered structure; and a physiologically active material layer, being stacked on the second micelle layer, comprising a physiologically active material, a water-soluble polymer, and a phenol derivative, and having a one or two-layered structure. | 2014-12-25 |
20140377323 | MEDICAL DEVICE COMPRISING COLLAGEN-VI - A medical device intended for insertion into a living body, which includes a non-biodegradable substrate having a tissue contact surface, wherein said tissue contact surface is at least partially coated with microfibrils of collagen VI. | 2014-12-25 |
20140377324 | Pharmaceutical Composition Comprising miRNA-100 And Its Use In The Modulation of Blood Vessel Growth and Endothelial Inflammation - Disclosed is a pharmaceutical composition comprising a miRNA-100 molecule or an antagomir thereof or a variant thereof for use as a medicament for the positive or negative modulation of blood vessel growth and vascular inflammation wherein the miRNA-100 or the miRNA antagomir has a homology of at least 85% to any of SEQ ID NO: 1, 2, 3 and/or 9. | 2014-12-25 |
20140377325 | COATINGS FOR IMPLANTABLE DEVICES COMPRISING POLYMERS OF LACTIC ACID AND METHODS FOR FABRICATING THE SAME - Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising polymers of lactic acid. | 2014-12-25 |
20140377326 | FABRICATION OF GELATIN HYDROGEL SHEET FOR THE TRANSPLANTATION OF CORNEAL ENDOTHELIUM - The invention provides a corneal endothelial composition comprising a transparent hydrogel scaffold and a single layer of cultured corneal endothelial cells on the surface of the scaffold. The hydrogel scaffold I comprised of at least one biopolymer, preferably gelatin. Also provided are methods of making a corneal endothelial scaffold | 2014-12-25 |
20140377327 | EXTENDED RELEASE DRUG-DELIVERY CONTACT LENSES AND METHODS OF MAKING - Contact lenses are described that include particles of polymer fiber mat incorporated into a polymer lens wherein the polymer fiber mat is formed by electrospinning a prepolymer solution. Methods for making the contact lenses with improved oxygen permeability are also described. Methods for making the contact lens with optional therapeutic drug delivery and refractive correction are also described. | 2014-12-25 |
20140377328 | INTRAORAL SOLUBLE-TYPE FILM PREPARATION - Provided is an intraoral soluble-type film preparation in which an unpleasant taste of a drug is masked. The intraoral soluble-type film preparation comprises a drug layer containing: a drug having a bitter taste and/or an astringent taste; an alkyl sulfate at a content of ¾ mol or more with respect to 1 mol of the drug; and a water-soluble polymer. | 2014-12-25 |
20140377329 | SUBLINGUAL FILMS - The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith. | 2014-12-25 |
20140377330 | Bioactive Hydrogel - The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds. | 2014-12-25 |
20140377331 | ANTIMICROBIAL WOUND-COVERING MATERIAL AND METHOD FOR MANUFACTURING SAME - The present invention relates to an antimicrobial wound dressing comprising chitosan-silver nanoparticles and a preparation method thereof The antimicrobial wound dressing is prepared by coating a wound dressing with chitosan and silver and drying the coated wound dressing and has an excellent property of releasing silver nanoparticles in a sustained manner. | 2014-12-25 |
20140377332 | NANOSHELLS ON POLYMERS - Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided. | 2014-12-25 |
20140377333 | DIETARY SUPPLEMENT COMPOSITIONS WITH ENHANCED DELIVERY MATRIX, AND METHODS OF MAKING THE SAME - A method of making dietary supplement compositions includes generating an aqueous phase, generating an oil phase, performing a first homogenizing step by mixing the aqueous and oil phases, adding reduced glutathione to the aqueous-oil composition and performing a second homogenizing step by mixing the aqueous-oil composition and reduced glutathione, adding a first flavor to the aqueous-oil-glutathione composition, performing a third homogenizing step by mixing the aqueous-oil-glutathione composition and the first flavor, adding xanthan gum dispersed with glycerin to the aqueous-oil-glutathione-first-flavor composition and performing a fourth homogenizing step by mixing the aqueous-oil-glutathione-first-flavor composition and xanthan gum; adding a second flavor to the aqueous-oil-glutathione-first-flavor-xanthan composition and performing a fifth homogenizing step by mixing the aqueous-oil-glutathione-first-flavor-xanthan composition and the second flavor so as to form a dietary supplement composition. Such method provides a dietary supplement as a dispersion including active ingredients incorporated in liposomal vesicles having a barrier coating of polyethylene glycol. | 2014-12-25 |
20140377334 | IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES - The invention provides compositions and methods for, inter alia, augmenting cell-based therapies in vivo by repeatedly stimulating target cells of interest over a period of time. | 2014-12-25 |
20140377335 | OPHTHALMIC FORMULATION - Disclosed herein is an ophthalmic formulation comprising a compound of formula (I): | 2014-12-25 |
20140377336 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA - The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism. | 2014-12-25 |
20140377337 | TRANSDERMAL APPLICATION OF PROSTAGLANDIN E1 FOR THE TREATMENT OF OCULAR ISCHEMIA - The invention concerns the use of a preparation based on prostaglandin E | 2014-12-25 |
20140377338 | TOPICAL MACQUI BERRY FORMULATION - The present invention provides a topical formulation and method of use where the formulation comprises macqui berry or a macqui berry extract containing anthocyanins having a very high oxygen radical absorbance capacity (ORAC). The formulation provides the macqui berry in a stabilized form which includes a glucuronide or glycuronide, a photostabilizing agent, encapsulation, or light- and/or air-blocking packaging. | 2014-12-25 |
20140377339 | TUSC2 THERAPIES - A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided. | 2014-12-25 |
20140377340 | HLA-DR BINDING PEPTIDES AND THEIR USES - The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines. | 2014-12-25 |
20140377341 | CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY - The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide. | 2014-12-25 |
20140377342 | WAFER AND CAPSULE FORMULATIONS WITH ENHANCED DISSOLUTION RATES FOR FENOFIBRATE - The objective of this invention is to develop a novel wafer and capsule formulations using fenofibrate which is difficult to dissolve and control its release rate in vitro. | 2014-12-25 |
20140377343 | FORMULATIONS OF FLURBIPROFEN AND DIACEREIN - The present invention relates to a pharmaceutical formulation, characterized by comprising flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, diacerein or a pharmaceutically acceptable salt of diacerein, as well as at least one or a properly-proportioned mixture of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or polyvinyl alcohol-polyethylene glycol copolymer. | 2014-12-25 |
20140377344 | PROTEASE INHIBITOR-CONTAINING COMPOSITIONS, COMPOSITIONS COMPRISING SAME, AND METHODS FOR PRODUCING AND USING SAME - Provided herein are methods and compositions for oral administration of therapeutic proteins, improved protease inhibitor preparations, methods for producing same, and compositions comprising same. | 2014-12-25 |
20140377345 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG - Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration. | 2014-12-25 |
20140377346 | BOSENTAN CONTROLLED RELEASE ORAL PREPARATION - Provided are an extended release preparation for oral administration of bosentan including bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof as an active ingredient and a hydrophilic polymer as a sustained release excipient, and a method of manufacturing the same. Accordingly, the number of administrations of the bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof may be reduced, thereby enhancing ease of administration and patient compliance. In addition, the extended release preparation for oral administration of bosentan may be effectively manufactured. | 2014-12-25 |